2025 Q4 -tulosraportti
16 päivää sitten
‧27 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·28.2.Insider buys Thursday, February 26th, CEO Carl Hansen bought 177457 Abcellera shares at 3.27 dollars via his company Thermopylae Holdings Ltd. Friday, February 27th, CFO Andrew Booth bought 42600 Abcellera shares at 3.42 dollars.- ·15.2.Bank of America steps in heavily in AbCellera – what does that mean for us shareholders? In Q3 2025, we have seen a remarkable movement among institutional investors in AbCellera (ABCL), where Bank of America (BoA) particularly stands out. According to official 13F reports, BoA has increased its holding from 224,365 to a full 2,418,304 shares – an incredible increase of +977.8 % in just one quarter! This makes BoA one of the largest new owners in AbCellera during the quarter, both in terms of number of shares and invested capital (approx. $12.16 million). MarketBeat has also noted that BoA is one of the institutions that bought the largest volume of ABCL shares over the past 24 months. And BoA is not alone. State of Michigan Retirement System increased its holding by 350,000 shares (+712 %) to a total of 400,000 shares during the same period. These are not small investors taking chances – these are major players making their moves based on deep analysis and long-term strategies. What does that tell us? It suggests that BoA sees something in AbCellera that is worth investing in – perhaps the company's AI-driven antibody development platform or their growing collaboration portfolio. At the same time, it's important to remember that ABCL still constitutes a very small part of BoA's total portfolio. It could therefore be part of a broader strategy for exposure to the biotechnology sector rather than a single bet. But the fact that one of the USA's largest banks significantly increases its stake in the company is a clear signal of confidence in AbCellera's potential. And that is something we as shareholders should note. Furthermore: Goldman Sachs increased its holding even more in Q4 – which strengthens the picture that institutional investors see long-term potential in AbCellera. Conclusion: This is a strong signal that something is happening. Perhaps it's time to dust off one's DD and consider whether to increase one's own exposure before the next report. After all, no negative news has come out, but the share price has fallen radically since the JP Morgan conference (which provided several positive news and advancements).
·20.2.How much have you invested in AbCellera? - ·23.1.AbCellera – The JPM effect in full swing? Following AbCellera's presentation at JP Morgan's Healthcare Conference on January 14, the stock has risen from 4.18 USD to 4.64 USD – an increase of approximately 11 % in just over a week. But what is really behind this movement? Is it just a temporary surge, or are we seeing the beginning of something bigger? Conclusion 1: When will the effect be visible in the stock? The JP Morgan conference is known for setting the tone for the year in biotech. Professional investors work methodically but under time pressure – some act immediately, others need weeks to analyze, get approval from investment committees, and start building positions. It is therefore not uncommon to see a delayed but steady rise in stocks that impressed at the conference. In AbCellera's case, we may very well be in the midst of this process. The price increase we have seen could be the first step in a longer trend where institutional capital begins to move into the stock. Historically, similar companies have shown gradual increases during Q1 after strong appearances at JPM – and it is precisely during February–March that the larger funds' buying decisions often begin to appear in the price chart and ownership lists. Conclusion 2: Likely institutional buying behind the increase There are several signs that it is not just retail investors behind the increase: -High trading volume – almost 7 million shares were traded on January 22, which is more than double the normal. -The price increase has occurred over several days, not as a single spike – a typical pattern for institutional accumulation. -News about phase 2 start for ABCL635 and pipeline expansion with ABCL688/386 provide clear triggers for long-term investors. -No signs of insider sales – rather a quiet period before year-end closing. -Early 13F-filings (a quarterly report that must be submitted to the US financial supervisory authority) show that some smaller funds have already started taking positions. It is, of course, impossible to say exactly who is buying, but the size of the trading suggests that several larger players are involved and building positions. If AbCellera continues to deliver according to plan – with clinical data later this year – this could very well be the beginning of a major revaluation of the company. Conclusion: The JPM effect has likely struck again. And if history repeats itself, we may see continued strength in the stock during Q1 – especially if more funds jump on board. And that is exactly what is happening now: institutional players have started taking their positions – and thereby the door is opened for a new wave of stock interested parties in AbCellera. When the big money starts to move, more often follow. This could very well be the start of a new phase in the company's stock market journey
- ·15.1. · Muokattuhttps://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/40de8a76-5969-4b19-b018-234b15e8cf95.pdf AbCellera – Delivery Update at the JP Morgan Conference and a New Position on the World Stage During JP Morgan's prestigious healthcare conference on January 14, 2026, AbCellera took a big step forward – not only in its pipeline, but in its position in the industry. The company presented four internal drug programs, two of which are already in clinical phase and two new ones are on their way in. The most striking? They are not just meeting their timelines – they are exceeding them. It's a signal that Big Pharma cannot ignore. - ABCL635 (for hot flashes) has entered Phase 2 after strong Phase 1 data. - ABCL575 (for atopic dermatitis) is in Phase 1 – data expected by summer. - New candidates: ABCL688 (autoimmune disease) and ABCL386 (oncology) in late preclinical phase. This means that AbCellera now has a pipeline with both breadth and depth – from women's diseases to immunology and oncology – and that the company shows it can drive several projects in parallel with high quality. It is a strong statement that demonstrates not only technical competence, but also organizational maturity. After a few tough years with high R&D costs and low revenue, the strategy is starting to yield results. With a strong cash position (~$680M) and a growing pipeline, AbCellera is better positioned than it has been in a long time. It is also worth noting that the company has built its own GMP facility for clinical manufacturing – a move that provides control, flexibility, and further accelerates development. But perhaps the most important message from the JP Morgan presentation was not just what AbCellera has done – but how they have done it. Delivering on (and ahead of) schedule in biotech is unusual. To do so with multiple projects simultaneously, in a time of cost pressure and regulatory challenges, is something that attracts attention. It signals reliability, pace, and cost-efficiency – three qualities that are crucial for gaining the trust of larger pharmaceutical companies. And this is precisely what makes the JP Morgan conference so important. It is not just a stage for showcasing data – it is a place where future partnerships are born. The fact that AbCellera is now able to speak at this type of forum, and deliver concrete progress there, is a clear sign that the company is in the process of transitioning from being a technological niche player to becoming a strategic partner for Big Pharma. This also creates an echo among investors. Institutional funds and long-term asset managers seek companies with potential, but also with a proven ability to deliver. AbCellera is now starting to demonstrate just that – and it is reasonable to assume that new investor collectives will begin to take positions. Worth keeping an eye on. 2026 could be the year AbCellera transitions from potential to real execution power – and establishes itself as a global player with both technical excellence and industrial credibility.·15.1. · MuokattuAbCellera: Two new candidates to keep an eye on – ABCL386 & ABCL688 AbCellera (ABCL) continues to build its internal pipeline with two exciting drug candidates in preclinical phase: - ABCL688 – targets a complex membrane protein (likely GPCR) for the treatment of a yet-to-be-disclosed autoimmune disease. The project entered IND-enabling studies during Q2 2025. Clinical trials are expected to start around 2027. - ABCL386 – an oncology candidate also in IND-enabling phase. Nominated as a development candidate during 2025, but details on target structure and indication are missing. Both projects are part of AbCellera's strategy to move from a partner-driven to a self-developed pipeline. The company has a strong cash position (~680MUSD) and aims to bring two new molecules to the clinic each year. Worth noting: No clinical data is available yet. There's a long way to market, but the technology is based on advanced targets that could provide competitive advantages if successful.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
16 päivää sitten
‧27 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·28.2.Insider buys Thursday, February 26th, CEO Carl Hansen bought 177457 Abcellera shares at 3.27 dollars via his company Thermopylae Holdings Ltd. Friday, February 27th, CFO Andrew Booth bought 42600 Abcellera shares at 3.42 dollars.
- ·15.2.Bank of America steps in heavily in AbCellera – what does that mean for us shareholders? In Q3 2025, we have seen a remarkable movement among institutional investors in AbCellera (ABCL), where Bank of America (BoA) particularly stands out. According to official 13F reports, BoA has increased its holding from 224,365 to a full 2,418,304 shares – an incredible increase of +977.8 % in just one quarter! This makes BoA one of the largest new owners in AbCellera during the quarter, both in terms of number of shares and invested capital (approx. $12.16 million). MarketBeat has also noted that BoA is one of the institutions that bought the largest volume of ABCL shares over the past 24 months. And BoA is not alone. State of Michigan Retirement System increased its holding by 350,000 shares (+712 %) to a total of 400,000 shares during the same period. These are not small investors taking chances – these are major players making their moves based on deep analysis and long-term strategies. What does that tell us? It suggests that BoA sees something in AbCellera that is worth investing in – perhaps the company's AI-driven antibody development platform or their growing collaboration portfolio. At the same time, it's important to remember that ABCL still constitutes a very small part of BoA's total portfolio. It could therefore be part of a broader strategy for exposure to the biotechnology sector rather than a single bet. But the fact that one of the USA's largest banks significantly increases its stake in the company is a clear signal of confidence in AbCellera's potential. And that is something we as shareholders should note. Furthermore: Goldman Sachs increased its holding even more in Q4 – which strengthens the picture that institutional investors see long-term potential in AbCellera. Conclusion: This is a strong signal that something is happening. Perhaps it's time to dust off one's DD and consider whether to increase one's own exposure before the next report. After all, no negative news has come out, but the share price has fallen radically since the JP Morgan conference (which provided several positive news and advancements).·20.2.How much have you invested in AbCellera?
- ·23.1.AbCellera – The JPM effect in full swing? Following AbCellera's presentation at JP Morgan's Healthcare Conference on January 14, the stock has risen from 4.18 USD to 4.64 USD – an increase of approximately 11 % in just over a week. But what is really behind this movement? Is it just a temporary surge, or are we seeing the beginning of something bigger? Conclusion 1: When will the effect be visible in the stock? The JP Morgan conference is known for setting the tone for the year in biotech. Professional investors work methodically but under time pressure – some act immediately, others need weeks to analyze, get approval from investment committees, and start building positions. It is therefore not uncommon to see a delayed but steady rise in stocks that impressed at the conference. In AbCellera's case, we may very well be in the midst of this process. The price increase we have seen could be the first step in a longer trend where institutional capital begins to move into the stock. Historically, similar companies have shown gradual increases during Q1 after strong appearances at JPM – and it is precisely during February–March that the larger funds' buying decisions often begin to appear in the price chart and ownership lists. Conclusion 2: Likely institutional buying behind the increase There are several signs that it is not just retail investors behind the increase: -High trading volume – almost 7 million shares were traded on January 22, which is more than double the normal. -The price increase has occurred over several days, not as a single spike – a typical pattern for institutional accumulation. -News about phase 2 start for ABCL635 and pipeline expansion with ABCL688/386 provide clear triggers for long-term investors. -No signs of insider sales – rather a quiet period before year-end closing. -Early 13F-filings (a quarterly report that must be submitted to the US financial supervisory authority) show that some smaller funds have already started taking positions. It is, of course, impossible to say exactly who is buying, but the size of the trading suggests that several larger players are involved and building positions. If AbCellera continues to deliver according to plan – with clinical data later this year – this could very well be the beginning of a major revaluation of the company. Conclusion: The JPM effect has likely struck again. And if history repeats itself, we may see continued strength in the stock during Q1 – especially if more funds jump on board. And that is exactly what is happening now: institutional players have started taking their positions – and thereby the door is opened for a new wave of stock interested parties in AbCellera. When the big money starts to move, more often follow. This could very well be the start of a new phase in the company's stock market journey
- ·15.1. · Muokattuhttps://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/40de8a76-5969-4b19-b018-234b15e8cf95.pdf AbCellera – Delivery Update at the JP Morgan Conference and a New Position on the World Stage During JP Morgan's prestigious healthcare conference on January 14, 2026, AbCellera took a big step forward – not only in its pipeline, but in its position in the industry. The company presented four internal drug programs, two of which are already in clinical phase and two new ones are on their way in. The most striking? They are not just meeting their timelines – they are exceeding them. It's a signal that Big Pharma cannot ignore. - ABCL635 (for hot flashes) has entered Phase 2 after strong Phase 1 data. - ABCL575 (for atopic dermatitis) is in Phase 1 – data expected by summer. - New candidates: ABCL688 (autoimmune disease) and ABCL386 (oncology) in late preclinical phase. This means that AbCellera now has a pipeline with both breadth and depth – from women's diseases to immunology and oncology – and that the company shows it can drive several projects in parallel with high quality. It is a strong statement that demonstrates not only technical competence, but also organizational maturity. After a few tough years with high R&D costs and low revenue, the strategy is starting to yield results. With a strong cash position (~$680M) and a growing pipeline, AbCellera is better positioned than it has been in a long time. It is also worth noting that the company has built its own GMP facility for clinical manufacturing – a move that provides control, flexibility, and further accelerates development. But perhaps the most important message from the JP Morgan presentation was not just what AbCellera has done – but how they have done it. Delivering on (and ahead of) schedule in biotech is unusual. To do so with multiple projects simultaneously, in a time of cost pressure and regulatory challenges, is something that attracts attention. It signals reliability, pace, and cost-efficiency – three qualities that are crucial for gaining the trust of larger pharmaceutical companies. And this is precisely what makes the JP Morgan conference so important. It is not just a stage for showcasing data – it is a place where future partnerships are born. The fact that AbCellera is now able to speak at this type of forum, and deliver concrete progress there, is a clear sign that the company is in the process of transitioning from being a technological niche player to becoming a strategic partner for Big Pharma. This also creates an echo among investors. Institutional funds and long-term asset managers seek companies with potential, but also with a proven ability to deliver. AbCellera is now starting to demonstrate just that – and it is reasonable to assume that new investor collectives will begin to take positions. Worth keeping an eye on. 2026 could be the year AbCellera transitions from potential to real execution power – and establishes itself as a global player with both technical excellence and industrial credibility.·15.1. · MuokattuAbCellera: Two new candidates to keep an eye on – ABCL386 & ABCL688 AbCellera (ABCL) continues to build its internal pipeline with two exciting drug candidates in preclinical phase: - ABCL688 – targets a complex membrane protein (likely GPCR) for the treatment of a yet-to-be-disclosed autoimmune disease. The project entered IND-enabling studies during Q2 2025. Clinical trials are expected to start around 2027. - ABCL386 – an oncology candidate also in IND-enabling phase. Nominated as a development candidate during 2025, but details on target structure and indication are missing. Both projects are part of AbCellera's strategy to move from a partner-driven to a self-developed pipeline. The company has a strong cash position (~680MUSD) and aims to bring two new molecules to the clinic each year. Worth noting: No clinical data is available yet. There's a long way to market, but the technology is based on advanced targets that could provide competitive advantages if successful.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
16 päivää sitten
‧27 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 6.11.2025 | ||
2025 Q2 -tulosraportti 7.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·28.2.Insider buys Thursday, February 26th, CEO Carl Hansen bought 177457 Abcellera shares at 3.27 dollars via his company Thermopylae Holdings Ltd. Friday, February 27th, CFO Andrew Booth bought 42600 Abcellera shares at 3.42 dollars.
- ·15.2.Bank of America steps in heavily in AbCellera – what does that mean for us shareholders? In Q3 2025, we have seen a remarkable movement among institutional investors in AbCellera (ABCL), where Bank of America (BoA) particularly stands out. According to official 13F reports, BoA has increased its holding from 224,365 to a full 2,418,304 shares – an incredible increase of +977.8 % in just one quarter! This makes BoA one of the largest new owners in AbCellera during the quarter, both in terms of number of shares and invested capital (approx. $12.16 million). MarketBeat has also noted that BoA is one of the institutions that bought the largest volume of ABCL shares over the past 24 months. And BoA is not alone. State of Michigan Retirement System increased its holding by 350,000 shares (+712 %) to a total of 400,000 shares during the same period. These are not small investors taking chances – these are major players making their moves based on deep analysis and long-term strategies. What does that tell us? It suggests that BoA sees something in AbCellera that is worth investing in – perhaps the company's AI-driven antibody development platform or their growing collaboration portfolio. At the same time, it's important to remember that ABCL still constitutes a very small part of BoA's total portfolio. It could therefore be part of a broader strategy for exposure to the biotechnology sector rather than a single bet. But the fact that one of the USA's largest banks significantly increases its stake in the company is a clear signal of confidence in AbCellera's potential. And that is something we as shareholders should note. Furthermore: Goldman Sachs increased its holding even more in Q4 – which strengthens the picture that institutional investors see long-term potential in AbCellera. Conclusion: This is a strong signal that something is happening. Perhaps it's time to dust off one's DD and consider whether to increase one's own exposure before the next report. After all, no negative news has come out, but the share price has fallen radically since the JP Morgan conference (which provided several positive news and advancements).·20.2.How much have you invested in AbCellera?
- ·23.1.AbCellera – The JPM effect in full swing? Following AbCellera's presentation at JP Morgan's Healthcare Conference on January 14, the stock has risen from 4.18 USD to 4.64 USD – an increase of approximately 11 % in just over a week. But what is really behind this movement? Is it just a temporary surge, or are we seeing the beginning of something bigger? Conclusion 1: When will the effect be visible in the stock? The JP Morgan conference is known for setting the tone for the year in biotech. Professional investors work methodically but under time pressure – some act immediately, others need weeks to analyze, get approval from investment committees, and start building positions. It is therefore not uncommon to see a delayed but steady rise in stocks that impressed at the conference. In AbCellera's case, we may very well be in the midst of this process. The price increase we have seen could be the first step in a longer trend where institutional capital begins to move into the stock. Historically, similar companies have shown gradual increases during Q1 after strong appearances at JPM – and it is precisely during February–March that the larger funds' buying decisions often begin to appear in the price chart and ownership lists. Conclusion 2: Likely institutional buying behind the increase There are several signs that it is not just retail investors behind the increase: -High trading volume – almost 7 million shares were traded on January 22, which is more than double the normal. -The price increase has occurred over several days, not as a single spike – a typical pattern for institutional accumulation. -News about phase 2 start for ABCL635 and pipeline expansion with ABCL688/386 provide clear triggers for long-term investors. -No signs of insider sales – rather a quiet period before year-end closing. -Early 13F-filings (a quarterly report that must be submitted to the US financial supervisory authority) show that some smaller funds have already started taking positions. It is, of course, impossible to say exactly who is buying, but the size of the trading suggests that several larger players are involved and building positions. If AbCellera continues to deliver according to plan – with clinical data later this year – this could very well be the beginning of a major revaluation of the company. Conclusion: The JPM effect has likely struck again. And if history repeats itself, we may see continued strength in the stock during Q1 – especially if more funds jump on board. And that is exactly what is happening now: institutional players have started taking their positions – and thereby the door is opened for a new wave of stock interested parties in AbCellera. When the big money starts to move, more often follow. This could very well be the start of a new phase in the company's stock market journey
- ·15.1. · Muokattuhttps://d18rn0p25nwr6d.cloudfront.net/CIK-0001703057/40de8a76-5969-4b19-b018-234b15e8cf95.pdf AbCellera – Delivery Update at the JP Morgan Conference and a New Position on the World Stage During JP Morgan's prestigious healthcare conference on January 14, 2026, AbCellera took a big step forward – not only in its pipeline, but in its position in the industry. The company presented four internal drug programs, two of which are already in clinical phase and two new ones are on their way in. The most striking? They are not just meeting their timelines – they are exceeding them. It's a signal that Big Pharma cannot ignore. - ABCL635 (for hot flashes) has entered Phase 2 after strong Phase 1 data. - ABCL575 (for atopic dermatitis) is in Phase 1 – data expected by summer. - New candidates: ABCL688 (autoimmune disease) and ABCL386 (oncology) in late preclinical phase. This means that AbCellera now has a pipeline with both breadth and depth – from women's diseases to immunology and oncology – and that the company shows it can drive several projects in parallel with high quality. It is a strong statement that demonstrates not only technical competence, but also organizational maturity. After a few tough years with high R&D costs and low revenue, the strategy is starting to yield results. With a strong cash position (~$680M) and a growing pipeline, AbCellera is better positioned than it has been in a long time. It is also worth noting that the company has built its own GMP facility for clinical manufacturing – a move that provides control, flexibility, and further accelerates development. But perhaps the most important message from the JP Morgan presentation was not just what AbCellera has done – but how they have done it. Delivering on (and ahead of) schedule in biotech is unusual. To do so with multiple projects simultaneously, in a time of cost pressure and regulatory challenges, is something that attracts attention. It signals reliability, pace, and cost-efficiency – three qualities that are crucial for gaining the trust of larger pharmaceutical companies. And this is precisely what makes the JP Morgan conference so important. It is not just a stage for showcasing data – it is a place where future partnerships are born. The fact that AbCellera is now able to speak at this type of forum, and deliver concrete progress there, is a clear sign that the company is in the process of transitioning from being a technological niche player to becoming a strategic partner for Big Pharma. This also creates an echo among investors. Institutional funds and long-term asset managers seek companies with potential, but also with a proven ability to deliver. AbCellera is now starting to demonstrate just that – and it is reasonable to assume that new investor collectives will begin to take positions. Worth keeping an eye on. 2026 could be the year AbCellera transitions from potential to real execution power – and establishes itself as a global player with both technical excellence and industrial credibility.·15.1. · MuokattuAbCellera: Two new candidates to keep an eye on – ABCL386 & ABCL688 AbCellera (ABCL) continues to build its internal pipeline with two exciting drug candidates in preclinical phase: - ABCL688 – targets a complex membrane protein (likely GPCR) for the treatment of a yet-to-be-disclosed autoimmune disease. The project entered IND-enabling studies during Q2 2025. Clinical trials are expected to start around 2027. - ABCL386 – an oncology candidate also in IND-enabling phase. Nominated as a development candidate during 2025, but details on target structure and indication are missing. Both projects are part of AbCellera's strategy to move from a partner-driven to a self-developed pipeline. The company has a strong cash position (~680MUSD) and aims to bring two new molecules to the clinic each year. Worth noting: No clinical data is available yet. There's a long way to market, but the technology is based on advanced targets that could provide competitive advantages if successful.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt